RiduZone is a 180mg oleoylethanolamide capsule with FDA new dietary ingredient acknowledgement, used as the intervention arm in a published Yale study.
Overview
RiduZone contains oleoylethanolamide, usually shortened to OEA, a lipid produced naturally in the small intestine after eating fat. OEA acts on PPAR-alpha receptors to signal satiety, and published research has examined how it modulates GLP-1 receptor signalling. It is one of the few compounds in this category with a defensible mechanistic link to the hormone the category is named after.
The product's credentials are unusual. Yale researchers used RiduZone as the active arm in a published dietary adaptation for weight loss maintenance study, with participants consuming RiduZone or placebo daily, each capsule containing 200mg of 90 percent OEA. That an independent university research team selected a specific commercial supplement for a trial is a genuinely rare distinction. RiduZone also received acknowledgement from the US FDA for its new dietary ingredient notification, a formal regulatory process that almost nothing else in this category has completed, and it has appeared in trial listings for weight loss maintenance.
The evidence should be described accurately. A published review found that OEA supplementation significantly reduced waist size in people with obesity, and a 2025 meta-analysis reported improvements in glycaemic control, weight, waist circumference, fat mass and inflammation. Those are encouraging findings from a small literature rather than settled conclusions. FDA acknowledgement addresses regulatory notification rather than efficacy. And RiduZone is a single-ingredient product, so it does nothing for protein, fibre or micronutrients.
RiduZone at a Glance
| Detail | What RiduZone Publishes |
|---|---|
| Type of product | Single-ingredient oleoylethanolamide capsule |
| Active content | 200mg of 90 percent OEA, delivering 180mg per capsule |
| Mechanism | PPAR-alpha satiety signalling, interacting with GLP-1 pathways |
| Notable use | The intervention arm in a published Yale study |
| Regulatory status | FDA acknowledgement of its new dietary ingredient notification |
| Meta-analysis findings | Improved glycaemic control, weight, waist circumference and fat mass |
| Marketing presence | Minimal |
| Retail availability | Limited |
| Formulation | Patented single ingredient rather than a blend |
| FDA evaluated for efficacy | No, as with all dietary supplements |
What Is Actually in It
- 180mg of oleoylethanolamide per capsule, from 200mg of 90 percent OEA
- A single named active ingredient rather than a blend
- A compound with published satiety and food intake research
- FDA acknowledgement of the new dietary ingredient notification
- The specific product used in a Yale research trial
- No protein, fibre or micronutrient content
Supplement or Medication?
A dietary supplement. OEA is a naturally occurring lipid your body already produces after eating fat. It signals satiety through PPAR-alpha and has been shown to modulate GLP-1 receptor signalling, which is a more direct mechanistic connection than most products here can claim.
How You Buy It
Find a stockist
Retail availability is limited compared with mass-market competitors.
Take as directed
Each capsule delivers 180mg of OEA.
Pair it with protein and fibre
This is a single-ingredient product covering neither.
Judge it over months
The Yale study examined weight loss maintenance over an extended period.
Who It Is Sold To
- Adults interested in a single-ingredient satiety compound
- No consultation or clinical assessment involved
- OEA is a naturally occurring compound with a good safety profile
- Not appropriate as a substitute for prescribed obesity treatment
- Speak to a clinician first if you take glucose-lowering medication
- You will need separate products for protein, fibre and micronutrients
Clinical Oversight and Evidence
Clinical Oversight
None at the point of sale. That said, this is the one product in the category that an independent university research team selected for a trial, which is a different kind of validation from a marketing claim.
Evidence
The most academically credentialed in this category, from a small literature. RiduZone was used as the intervention arm in a published Yale dietary adaptation for weight loss maintenance study. A published review found OEA significantly reduced waist size in people with obesity, and a 2025 meta-analysis reported improvements in glycaemic control, weight, waist circumference, fat mass and inflammation. Separate published work has examined how OEA modulates GLP-1 receptor signalling.
Availability and Shipping
Where to Buy
Direct and through limited retail channels. RiduZone has minimal consumer marketing compared with the rest of this category.
Shipping
Standard shipping for shelf-stable capsules.
What You Get
- Use as the intervention arm in an independent university trial
- FDA acknowledgement of its new dietary ingredient notification
- A published meta-analysis on the active compound
- A single named ingredient at a stated dose
- A patented formulation
- Almost no marketing, and limited retail availability
Pricing
Modest consumer visibility means pricing is less standardised than mass-market competitors.
| Product or Plan | Published Price | What It Covers |
|---|---|---|
| RiduZone | Direct pricing | 180mg OEA per capsule |
| Capsule content | 200mg of 90 percent OEA | As specified in the Yale study |
| Retail availability | Limited | Fewer channels than mass-market brands |
| Subscription | Varies | Depends on the channel |
Pricing reflects what RiduZone published at the time of review and can change without notice. Confirm current pricing directly with the seller before buying.
Membership Fees
None. Ordinary retail purchasing.
Annual Cost
Depends on channel. As a single-ingredient product it avoids the bundle pricing that inflates several competitors.
Cancellation and Refund Policy
Cancellation
Not applicable to ordinary retail purchases.
Refunds
Varies by channel.
Insurance, HSA and FSA
Insurance
Not applicable to a retail supplement.
HSA / FSA
Generally not eligible. Dietary supplements are usually excluded from HSA and FSA spending without a letter of medical necessity from a clinician.
For a fuller explanation of how these accounts work with GLP-1 care, see our GLP-1 insurance, HSA and FSA guide.
Who RiduZone May Be Best For
- You want the ingredient with the most academic credentialing here
- You value a single named active at a stated dose
- You are interested in the OEA satiety mechanism specifically
- You are getting protein and fibre from elsewhere
- You care more about research than marketing
- You are willing to hunt for a stockist
- The OEA literature is small, though promising
- FDA acknowledgement is regulatory, not an efficacy endorsement
- Almost no consumer visibility or support
- Limited retail availability
- A single ingredient covering none of the nutrition problems
- Being used in a trial is not the same as the trial succeeding
Alternatives to Consider
Force Factor Super GLP-1 Support
Published human GLP-1 trials, and far easier to buy.
Calocurb
Amarasate hops extract with appetite-specific trials.
Ora Organic GLP-1 Up
Four patented extracts at stated clinical doses.
Bariatric Fusion GLP-ONE
Receptor-targeted botanicals at $29.99.
You can also compare the whole field in our best GLP-1 supplements and GLP-1 supplement evidence review roundups.
Frequently Asked Questions
What is OEA?
Oleoylethanolamide, a lipid your small intestine produces naturally after eating fat. It signals satiety through PPAR-alpha receptors, and published research has examined how it modulates GLP-1 receptor signalling.
Was it really used in a Yale study?
Yes. Yale researchers used RiduZone as the intervention arm in a published dietary adaptation for weight loss maintenance study, with each capsule containing 200mg of 90 percent OEA. An independent university team selecting a specific commercial supplement is genuinely unusual.
What does FDA acknowledgement mean?
RiduZone received acknowledgement of its new dietary ingredient notification, a formal regulatory process. It confirms the notification was accepted; it does not mean the FDA has endorsed the product's effectiveness.
Does OEA work?
The evidence is promising rather than settled. A published review found OEA significantly reduced waist size in people with obesity, and a 2025 meta-analysis reported improvements in glycaemic control, weight, waist circumference, fat mass and inflammation. The literature is small.
Why is it so little known?
It has almost no consumer marketing compared with the rest of this category, which spends heavily. That is an odd inversion given its research credentials.
Do I need anything else alongside it?
Yes. This is a single-ingredient product providing no protein, fibre or micronutrients, all of which matter more than any satiety compound if you are eating substantially less.
Is it FDA approved?
No. It is a dietary supplement, so it does not require FDA approval before marketing and its claims have not been evaluated by the FDA for efficacy.